Navigation Links
Trubion Pharmaceuticals Inc. Reports Second-Quarter and First-Half 2010 Financial Results
Date:8/16/2010

SEATTLE, Aug. 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced financial results for its second quarter and six months ended June 30, 2010.

(Logo: http://photos.prnewswire.com/prnh/20090320/TRUBIONLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Second-Quarter and First-Half 2010 Financial ResultsRevenue for the second quarter and six months ended June 30, 2010, increased to $5.7 million and $11.2 million, respectively, compared with $4.1 million and $8.3 million, respectively, in 2009. Revenue was primarily earned through the company's strategic collaborations with Pfizer, for the development of CD20-directed candidates, including SBI-087, and Abbott, for the development of CD37-directed targets, including TRU-016.

During the second quarter and first half of 2010, Trubion recognized $3.8 million in revenue from its Abbott collaboration. The $3.8 million includes recognition of $1.1 million from the $20 million upfront fee and $1.4 million equity premium received from Abbott, as well as $2.7 million earned through collaborative research.

The increase in revenue from the Abbott partnership was partially offset by lower revenue generated by Trubion's collaboration with Pfizer. The decrease in revenue was attributed to lower costs related to the retreatment studies of TRU-015 for rheumatoid arthritis (RA) as well as a decrease in the amount of reimbursable legal fees. Revenue earned from Trubion's partnership with Pfizer during the first half of the year was $7.4 million, which included $2.4 million for recognition of the $40 million upfront fee received in January 2006 and $5.0 million earned through collaborative research. This is compared with $8.
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
6. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
7. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
8. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
9. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
10. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
11. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Diabetes Care, American Association of Diabetes Educators, ... Asante Solutions, A. Menarini, Bayer Group, Bayer ... Centres for Medicare and Medicaid Services ( ... Control and Prevention (CDC), Carlyle Group, Cascade ... Covidien, Cygnus, ConvaTec, Constitution Medical Investor, Dexcom, ...
(Date:3/1/2015)... /CNW Telbec/ -   Ergoresearch Ltd (TSXV: ERG) – ... under the « Équilibre, orthèses et biomécanique» banner ... on December 31, 2014. All dollar amounts in the ... Revenues for the second quarter of fiscal year 2015 ... by 8,8 % compared to revenues of $ 4 489 ...
(Date:3/1/2015)... ATLANTA , March 1, 2015  Patients ... new weapon against this debilitating foot ailment, according ... Interventional Radiology ,s Annual Scientific Meeting . ... to penetrate, emulsify and remove diseased fasciitis tissue. ... healthy tissue to regrow in its place, restoring ...
Breaking Medicine Technology:Blood Glucose Meters Industry 2019 Forecasts for Global and Chinese Regions 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 3Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 4Interventional radiology treatment relieves chronic plantar fasciitis 2Interventional radiology treatment relieves chronic plantar fasciitis 3
... Dynatronics Corporation (Nasdaq: DYNT ) announced ... RB Milestone Portfolio, a group of companies selected by ... the market via a combination of traditional and innovative ... Network™, and non-deal roadshows, with a focus on the ...
... 16, 2011 McGraw-Hill Professional, a leading ... scientific and medical communities, and Simbionix™, the ... simulation technology, have partnered to bring surgical ... training resource AccessSurgery™ ( www.accesssurgery.com ) to ...
Cached Medicine Technology:Dynatronics Selected for Inclusion in RB Milestone Portfolio 2McGraw-Hill Professional and Simbionix™ Partner to Provide Enhanced Surgical Simulation and Education 2
(Date:3/1/2015)... Comparing a new source of vehicle ... Quotes Pros portal this year. A broad range of ... that are being supplied through the finder at ... prices available for each policy is now provided in ... user will first be asked to present their unique ...
(Date:3/1/2015)... March 01, 2015 A federal ... http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to trial in ... a witness to provide testimony regarding the role ... of the Profemur device, Bernstein Liebhard LLP comments. ... Court, Northern District of Iowa on February 25th, ...
(Date:3/1/2015)... 01, 2015 Indiana Fiber Network, ... Provider, announces NewWays Networking, LLC (NewWays) selected IFN ... with IFN, NewWays is well positioned to scale ... for Internet bandwidth in rural parts of Indiana,” ... to Cory Childs IFN Enterprise Sales Manager, IFN ...
(Date:3/1/2015)... California (PRWEB) March 01, 2015 Theme ... a new transition pack for Final Cut ... add accordion style transitions to any FCPX editors project.” ... given our users the tools needed to easily drag ... , The user gets many different controls over the ...
(Date:2/28/2015)... February 28, 2015 In recent years Medical ... of practicing physicians as a way for them to expand ... regarding Cannabis as medicine. Since the FDA still lists Cannabis ... resources available to licensed physicians that can help guide ... Dr. Deborah Malka in Santa Cruz, CA is a ...
Breaking Medicine News(10 mins):Health News:United Auto Insurance Rates Now Quoted at Consumer Insurance Portal Online 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2
... in Canada,s north, Canada would benefit from enhanced relationships ... CMAJ ( Canadian Medical Association Journal ) ... looks at health and health care in Canada,s north ... includes Alaska in the US, Norway, Sweden, Finland, Russia, ...
... was diagnosed in 2007 with acute multiple myeloma, a form ... troubles all those who receive an upsetting diagnosis. The way ... however, was different. Barrager drew upon his engineering and management ... is sharing his insights with hospitals and doctors in his ...
... Reporter , MONDAY, Nov. 1 (HealthDay News) -- Pain is a ... reports of pain increasing during the final few months, a new ... being "troubled" by moderate or severe pain two years before they ... had jumped to nearly half. "This study shows that ...
... , MONDAY, Nov. 1 (HealthDay News) -- The success ... fat (MUFA), which are commonly found in nuts, seeds, avocados, ... oil, new research suggests. In the study, researchers randomly ... moderate elevated cholesterol levels to either a high-MUFA diet or ...
... , MONDAY, Nov. 1 (HealthDay News) -- Stroke ... the hospital on the weekend instead of a weekday, regardless ... Canadian researchers analyzed data from almost 21,000 stroke patients ... Only patients with their first stroke were included in the ...
... National Jewish Health has received a US patent for ... help assure many patients that dramatic changes in lifestyle ... PhD, Medical Director of the Advanced Diagnostic Laboratories at ... Donald MacGlashan, Jr. developed the diagnostic assay, which makes ...
Cached Medicine News:Health News:Management science guru, surviving cancer, offers hope to fellow sufferers, doctors 2Health News:Management science guru, surviving cancer, offers hope to fellow sufferers, doctors 3Health News:Almost Half of Elderly Report Pain in Life's Final Months 2Health News:Almost Half of Elderly Report Pain in Life's Final Months 3Health News:Adding Monounsaturated Fats to Diet May Boost Heart Health 2Health News:Weekend Admissions Worse for Stroke Victims: Study 2Health News:National Jewish Health receives patent for diagnostic method of autoimmune chronic urticaria 2
Sterile perfluorocarbon for intraocular Application....
Silikon 1000 (purified polydimethylsiloxane) is a highly purified long chain polydimethylsiloxane trimethylsiloxy terminated silicone oil. For use as a postoperative retinal tamponade during vitreore...
... hard contact lens cleaning solution ... use, and professionally proven cleaner. ... detergents resulting in a very ... deposits, cosmetic residue, salts, mucous ...
4.625 inches, curved blade 4 mm....
Medicine Products: